Wuhan YZY Biopharma Co., Ltd. Class H (2496) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 920.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.23
• Revenue Growth: N/A
• EPS Growth: 57.57%
• Country: HK
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 111,468,810
• 10 Day Avg. Volume: 40
• 30 Day Avg. Volume: 920
• PEG Ratio: 0.28
• Price to Book (P/B): 49.37
• Price to Sales (P/S): 13.98
• P/FCF Ratio: -14.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$5.50
• Price Target Upside: -19.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: HK$5.50 ▼(-19.47% Downside)

The overall stock score of 50 reflects significant financial challenges, including consistent net losses and high leverage, which weigh heavily on the score. Technical analysis provides a neutral outlook, while valuation is hindered by negative earnings. The absence of earnings call data and corporate events limits additional insights.

Wuhan YZY Biopharma Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.

How the Company Makes Money

Wuhan YZY Biopharma generates revenue primarily through the commercialization of its proprietary therapeutic products. The company engages in the sale of monoclonal antibodies and other biologic drugs developed in-house. Revenue streams include direct sales to healthcare providers and partnerships with pharmaceutical companies for distribution and co-development. Licensing agreements and collaborations with other biotech firms also contribute to its income, allowing YZY Biopharma to leverage its technology platforms and intellectual property for broader market reach. Additionally, the company may receive funding through government grants and research collaborations aimed at advancing its R&D pipeline.

Wuhan YZY Biopharma Co., Ltd. Class H Financial Statement Overview

Summary

Wuhan YZY Biopharma faces significant financial hurdles, with consistent net losses and high leverage. While revenue growth is promising, profitability and cash flow issues remain critical areas for improvement. Strategic cost management and efficient capital allocation will be essential for future financial stability.

Income Statement

The income statement shows a challenging environment with consistent net losses and negative EBIT and EBITDA margins. Gross profit margin is high at 78.90%, but net profit margin is negative due to substantial operating expenses. Revenue growth is strong at 804.06%, indicating potential for future improvement if expenses can be curtailed.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio of 4.17, which suggests significant leverage. The equity ratio is low at 11.40%, indicating limited equity financing. Return on equity is negative, driven by net losses, signifying the need for operational improvements to enhance shareholder value.

Cash Flow

Cash flow analysis highlights negative free cash flow, though there is a healthy operating cash flow to net income ratio of 1.03, suggesting better cash management relative to net income. Continued negative free cash flow growth is a concern, indicating cash outflows exceed inflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	149.35M	107.81M	11.92M	2.26M	12.18M
Gross Profit	97.08M	85.07M	11.92M	2.26M	12.18M
EBITDA	-70.08M	-86.95M	-158.39M	-169.23M	-125.20M
Net Income	-78.04M	-97.60M	-190.98M	-188.87M	-148.52M
Balance Sheet
Total Assets	239.63M	267.84M	301.62M	265.92M	163.33M
Cash, Cash Equivalents and Short-Term Investments	166.18M	126.28M	196.68M	200.52M	83.71M
Total Debt	156.66M	127.35M	90.11M	67.32M	23.24M
Total Liabilities	267.07M	237.31M	173.97M	129.05M	46.51M
Stockholders Equity	-27.45M	30.54M	127.65M	155.88M	143.16M
Cash Flow
Free Cash Flow	-31.11M	-102.22M	-187.95M	-156.40M	-82.10M
Operating Cash Flow	-30.34M	-100.72M	-186.02M	-155.16M	-80.55M
Investing Cash Flow	132.00K	-4.67M	54.81M	5.10M	-16.27M
Financing Cash Flow	32.10M	33.02M	176.29M	241.33M	81.03M

Wuhan YZY Biopharma Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2496, the sentiment is Positive. The current price of 6.83 is above the 20-day moving average (MA) of 6.42, above the 50-day MA of 5.92, and above the 200-day MA of 5.67, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 93.93 is Negative, neither overbought nor oversold. The STOCH value of 41.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2496.

Wuhan YZY Biopharma Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.66B	206.67	0.99%	―	9.41%	-32.69%
2257	57 Neutral	HK$1.38B	―	-266.90%	―	―	83.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2197	51 Neutral	HK$3.63B	―	―	―	79.98%	-3.40%
2496	50 Neutral	―	―	-723.86%	―	―	57.57%
6628	45 Neutral	HK$1.75B	―	-34.18%	―	-57.84%	24.58%
2126	41 Neutral	HK$1.80B	―	-51.56%	―	2.45%	2.58%

Wuhan YZY Biopharma Co., Ltd. Class H Corporate Events

Wuhan YZY Biopharma Reports Interim 2025 Financial Results Amid R&D Focus

Wuhan YZY Biopharma Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, reporting a revenue of RMB 37,187,000 and a gross profit of RMB 7,669,000. Despite a decrease in research and development expenses compared to the previous year, the company reported a loss of RMB 58,834,000, highlighting ongoing financial challenges. The results reflect the company’s continued investment in R&D, impacting its financial performance but potentially positioning it for future growth in the biopharmaceutical sector.

The most recent analyst rating on (HK:2496) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Wuhan YZY Biopharma Co., Ltd. Class H stock, see the HK:2496 Stock Forecast page.

Wuhan YZY Biopharma Schedules Board Meeting to Review Interim Results

Wuhan YZY Biopharma Co., Ltd. has announced a board meeting scheduled for August 26, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming months.

Wuhan YZY Biopharma Announces AGM Results and Board Elections

Wuhan YZY Biopharma Co., Ltd. announced the results of its annual general meeting held on June 25, 2025, where key resolutions were approved, including the election of a new board and supervisory committee, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. The meeting saw high shareholder participation with over 85% of voting rights represented, reflecting strong stakeholder engagement and support for the company’s strategic direction.

Wuhan YZY Biopharma Announces Board Composition and Roles

Wuhan YZY Biopharma Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the company’s governance structure and may impact its strategic direction and decision-making processes, potentially affecting stakeholders and the company’s position in the biopharmaceutical industry.